Table Info

Table 2.

Comparison of discrete variables between patients showing (DISH+) and not showing (DISH–) radiographic features of DISH

Variables		DISH+/total	Percentage of DISH+ among the total (%)	P
Sex	Male	30/101	29.70	0.021
Sex	Female	1/20	5.00	0.021
Diuretics	Yes	17/62	27.42	0.642
Diuretics	No	14/59	23.73	0.642
Tophi	Yes	8/28	28.57	0.683
Tophi	No	23/93	24.73	0.683
Previous ULT	Yes	12/49	24.49	0.814
Previous ULT	No	19/72	26.39	0.814
Hypertension	Yes	29/100	29.00	0.063
Hypertension	No	2/21	9.52	0.063
Hyperlipidemia	Yes	18/74	24.32	0.682
Hyperlipidemia	No	13/47	27.66	0.682
Diabetes	Yes	11/41	24.39	0.827
Diabetes	No	20/80	25.00	0.827
Vascular event (previous)	Yes	11/46	23.91	0.736
Vascular event (previous)	No	20/75	26.67	0.736
Polyarticular (joint involvement)	Yes	15/38	39.47	0.018
Polyarticular (joint involvement)	No	16/83	19.28	0.018
Obesity (BMI > 30)	Yes	3/14	21.43	0.702
Obesity (BMI > 30)	No	28/107	26.17	0.702
CPPA	Yes	6/14	42.86	0.116
CPPA	No	25/107	23.36	0.116

ULT: urate lowering treatment

Declarations

Author contributions

FPR: Conceptualization, Data curation. FPR, Nuria PH, CVP, MdCMC, Nerea PH, and AMHB: Data curation. FPR, Nuria PH, CVP, MdCMC, Nerea PH, and AMHB: Writing—review & editing. FPR, Nuria PH, CVP, MdCMC, Nerea PH, and AMHB read and approved the submitted version.

Conflicts of interest

FPR is consultant for Arthrosi, Horizon, LG pharma, Protalix, and SOBI; member of DMSB for Selecta; speaker for Menarini, EULAR, and Spanish Foundation for Rheumatology.

Ethical approval

The study was included within a prospective inception gout cohort study approved by Cruces University Hospital Ethics and Clinical Investigation Committee (CEIC Cruces).

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

Data could be obtained on request by contacting Prof. Dr. Fernando Pérez-Ruiz (fernando.perezruiz@osakidetza.eus).

Funding

FPR was funded by a grant from Asociación de Reumatólogos de Cruces [05/2022]. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Forestier J, Rotes-Querol J. Senile vertebral ankylosing hyperostosis. Rev Rhum Mal Osteoartic. 1950;17:525–34. Undetermined language. [PubMed]

Resnick D, Shaul SR, Robins JM. Diffuse idiopathic skeletal hyperostosis (DISH): Forestier’s disease with extraspinal manifestations. Radiology. 1975;115:513–24. [DOI] [PubMed]

Resnick D, Niwayama G. Radiographic and pathologic features of spinal involvement in diffuse idiopathic skeletal hyperostosis (DISH). Radiology. 1976;119:559–68. [DOI] [PubMed]

Kiss C, Szilágyi M, Paksy A, Poór G. Risk factors for diffuse idiopathic skeletal hyperostosis: a case–control study. Rheumatology (Oxford). 2002;41:27–30. [DOI] [PubMed]

Mader R, Novofestovski I, Adawi M, Lavi I. Metabolic syndrome and cardiovascular risk in patients with diffuse idiopathic skeletal hyperostosis. Semin Arthritis Rheum. 2009;38:361–5. [DOI] [PubMed]

Stĕpán J, Sváb V, Kolár J, Susta A, Cáp F. The spine and polytopic hyperostoses in gout and hyperuricemia. Radiologe. 1983;23:371–4. German. [PubMed]

Mituszova M, Judák A, Poór G, Gyódi E, Stenszky V. Clinical and family studies in Hungarian patients with gout. Rheumatol Int. 1992;12:165–8. [DOI] [PubMed]

Littlejohn GO, Hall S. Diffuse idiopathic skeletal hyperostosis and new bone formation in male gouty subjects. A radiologic study. Rheumatol Int. 1982;2:83–6. [DOI] [PubMed]

Hsu CM, Hsu CC, Wu RW, Huang CC, Chen YC. Interplay between fat, muscle, bone mass, and oteophytes and risk for tophaceous gout. J Investig Med. 2023;71:58–61. [DOI] [PubMed]

10.

Ahmed O, Ramachandran K, Patel Y, Dhanapaul S, Meena J, Shetty AP, et al. Diffuse idiopathic skeletal hyperostosis prevalence, characteristics, and associated comorbidities: a cross-sectional study of 1815 whole spine CT scans. Global Spine J. 2022;[Epub ahead of print]. [DOI] [PubMed]

11.

Ikuma H, Hirose T, Nakamura D, Yamashita K, Ueda M, Sasaki K, et al. The prevalence and characteristics of diffuse idiopathic skeletal hyperostosis (DISH): a cross-sectional study of 1519 Japanese individuals. Diagnostics (Basel). 2022;12:1088. [DOI] [PubMed] [PMC]

12.

Sencan D, Elden H, Nacitarhan V, Sencan M, Kaptanoglu E. The prevalence of diffuse idiopathic skeletal hyperostosis in patients with diabetes mellitus. Rheumatol Int. 2005;25:518–21. [DOI] [PubMed]

13.

Denko CW, Malemud CJ. Role of the growth hormone/insulin-like growth factor-1 paracrine axis in rheumatic diseases. Semin Arthritis Rheum. 2005;35:24–34. [DOI] [PubMed]

14.

Mader R, Pappone N, Baraliakos X, Eshed I, Sarzi-Puttini P, Atzeni F, et al. Diffuse idiopathic skeletal hyperostosis (DISH) and a possible inflammatory component. Curr Rheumatol Rep. 2021;23:6. [DOI] [PubMed]

15.

Pappone N, Di Minno MN, Iervolino S, Lupoli R, Mader R, Zincarelli C, et al. The impact of concomitant diffuse idiopathic skeletal hyperostosis on the achievement of minimal disease activity in subjects with psoriatic arthritis. Rheumatol Int. 2015;35:2041–6. [DOI] [PubMed]

16.

Kleiber Balderrama C, Rosenthal AK, Lans D, Singh JA, Bartels CM. Calcium pyrophosphate deposition disease and associated medical comorbidities: a national cross-sectional study of US veterans. Arthritis Care Res (Hoboken). 2017;69:1400–6. [DOI] [PubMed] [PMC]

17.

Bruges-Armas J, Couto AR, Timms A, Santos MR, Bettencourt BF, Peixoto MJ, et al. Ectopic calcification among families in the Azores: clinical and radiologic manifestations in families with diffuse idiopathic skeletal hyperostosis and chondrocalcinosis. Arthritis Rheum. 2006;54:1340–9. [DOI] [PubMed]

18.

Parreira B, Couto AR, Rocha F, Sousa M, Faustino V, Power DM, et al. Whole exome sequencing of patients with diffuse idiopathic skeletal hyperostosis and calcium pyrophosphate crystal chondrocalcinosis. Acta Reumatol Port. 2020;45:116–26. [PubMed]

19.

Duran E, Bilgin E, Ertenli Aİ, Kalyoncu U. The frequency of Achilles and plantar calcaneal spurs in gout patients. Turk J Med Sci. 2021;51:1841–8. [DOI] [PubMed] [PMC]